Reading TGTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TGTX free→Reading TGTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TGTX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality is fragile, meaning profits lack cash support. Management's recent track record has been steady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, TGTX is typical. Peer multiples imply a price about 360% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. Rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. If TGTX cuts guidance on the next call, that would be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $50.30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $50, TGTX's earnings are too small for P/E to mean much; on sales it trades at 77× p/e (4.6× the 17× p/e peer median, and 1.2× even its own history). At a normal multiple the price implies ~161% near-term growth vs our ~100% forecast. That gap is an optionality premium a financial-multiple model can't price — our $19 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 161% near-term growth, well above our forecast of about 100%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -0.03x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.46 → $0.43 (-6.4% / 30d). 5 raised, 0 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 78% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$141.
How much price usually moves either way.
On a bad day, this stock has moved -$348.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,266.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This data will show if the new single infusion works. Good results could help BRIUMVI's market.
Confirms:Topline results show the new single infusion works like the current regimen.
Disproves:Topline results do not show the new regimen works. It is not effective.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TGTX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TGTX TG Therapeutics, Inc. | Typical Show detailsSector percentile: 39 of 100 | expensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
2 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
TG Therapeutics aims to increase BRIUMVI revenue guidance based on strong market demand and performance.
TG Therapeutics is focused on expanding the BRIUMVI franchise through new formulations and market penetration.
TG Therapeutics aims to manage operating expenses with a target of $350 million for 2026.
Focus on increasing revenue through strategic initiatives and market expansion.
Enhance operating income through cost management and efficiency improvements.
Why it matters: This will show if the company's growth strategy is still working. A drop could signal trouble.
Confirms:Q2 revenue growth reported below 25% year over year.
Disproves:Q2 revenue growth remains at or above 25% year over year.
Why it matters: This figure will show if BRIUMVI's growth momentum continues. Strong revenue could support management's guidance increase.
Confirms:Q2 BRIUMVI U.S. net product revenue exceeds $220 million.
Disproves:Q2 BRIUMVI U.S. net product revenue falls below $220 million.
Why it matters: Progress on this project could increase BRIUMVI's market chances. Success helps long-term growth.
Confirms:News about progress or good results in the subcutaneous BRIUMVI program.
Disproves:No news or bad results about BRIUMVI's skin injection development.
Why it matters: This shows the company is managing costs well. A rise in operating income is a good sign.
Confirms:Q2 operating income was over $40M.
Disproves:Q2 operating income was under $30M.
Why it matters: A drop in sector growth could hurt TG Therapeutics. It shows broader challenges in the health care sector.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains above its median.
Why it matters: Higher costs could hurt profits and cash flow. Keeping costs down is key for growth.
Confirms:Operating costs reported at or below $350 million for 2026.
Disproves:Operating costs are over $350 million for 2026.
Why it matters: This would indicate a setback in achieving positive net income. It could hurt investor confidence.
Confirms:Q2 net income reported as negative.
Disproves:Q2 net income reported as positive.
Entry into Material Definitive Agreement On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement, dated as of August 2, 2024 (as amended, restated, amended…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.